tirzepatide approval canada — 10 mg B.C. limits sale of 2
Description
Effectiveness for Weight Management Clinical studies have demonstrated that tirzepatide can lead to substantial weight loss
In the MASH liver trials, discontinuation studies are still limited, but early data suggests liver enzyme improvements and histological gains are not maintained without ongoing treatment
Some individuals discontinue with plans to restart if regain becomes excessive
Regularly inspect vials for seal integrity
It is unknown whether tirzepatide passes into human breast milk, as no studies have been conducted in lactating individuals
The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease.
